RecruitingPHASE1, PHASE2NCT07589543

Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer

Studying Primary peritoneal tumor

Last synced from ClinicalTrials.gov May 18, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Beijing Biotech
Intervention: EB-DUALNK(biological)
Enrollment: 42 target
Eligibility: 18-75 years · FEMALE
Timeline: 2026 – 2028

Study locations (1)

Peking University Shenzhen Hospital, Shenzhen, Guangdong, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07589543 on ClinicalTrials.gov

Other trials for Primary peritoneal tumor

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07586826
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
Peking University People's Hospital
ACTIVE NOT RECRUITINGNCT06483997
Diet, Hepcidin, and Chemotherapy RDI
George Washington University
ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02726997
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
M.D. Anderson Cancer Center

See all trials for Primary peritoneal tumor →

← Back to all trials